Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants

(2021) Suzanne E. Schindler et al.   Neurology-Genetics

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

(2021) Tim West et al.   Molecular Neurodegeneration

Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers

(2021) Shorena Janelidze et al.   Alzheimers & Dementia

Comparative analytical performance of multiple plasma amyloid‐beta assays and their relationship to amyloid PET

(2021) Stephen Zicha et al.   Alzheimers & Dementia

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy

(2020) Kathryn Gauthreaux et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

(2020) James D. Doecke et al.   Alzheimers Research & Therapy

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

(2020) Reisa A. Sperling et al.   JAMA Neurology

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Factors Associated with Lumbar Puncture Participation in Alzheimer’s Disease Research

(2020) Madeleine M. Blazel et al.   JOURNAL OF ALZHEIMERS DISEASE

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease

(2020) Kanta Horie et al.   BRAIN

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease

(2019) John C. Morris et al.   JAMA Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL

(2018) Pierrick Bourgeat et al.   NEUROIMAGE

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

(2018) Leslie M. Shaw et al.   Alzheimers & Dementia

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

(2018) Itziar de Rojas et al.   Alzheimers Research & Therapy

The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics

(2017) Lindsay K. Pino et al.   MASS SPECTROMETRY REVIEWS

Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

(2016) Flora H. Duits et al.   Alzheimers & Dementia

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience

(2016) Jennifer C. Howell et al.   Frontiers in Aging Neuroscience

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

(2013) Keith A. Johnson et al.   Alzheimers & Dementia

Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics

(2013) Kwasi G. Mawuenyega et al.   ANALYTICAL BIOCHEMISTRY

Amyloid-  Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods

(2012) S. M. Landau et al.   JOURNAL OF NUCLEAR MEDICINE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

(2011) Christopher M. Clark   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

(2010) Rik Vandenberghe et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

(2010) Christopher C. Rowe et al.   NEUROBIOLOGY OF AGING

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

(2009) Kathryn A Ellis et al.   INTERNATIONAL PSYCHOGERIATRICS

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY